Navigation Links
Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
Date:2/4/2009

SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the 11th Annual BIO CEO & Investor Conference. The details are as follows:

    Corporate Presentation:
    Date:  Monday, February 9, 2009
    Time:  3:45 p.m. - 4:15 p.m. Eastern
    Location: Waldorf Astoria, Astor Room, New York
    Speaker: Graham Cooper, Chief Financial Officer

    Panel Discussion:
    Feeding the Need for New Treatments in Obesity
    Date:  Monday, February 9, 2009
    Time:  11:00 a.m. - 12:10 p.m. Eastern
    Location: Waldorf Astoria, East Foyer, New York
    Speaker: Dr. Dennis Kim, Senior Vice President, Corporate Development

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave, which is in Phase 3 clinical trials, and Empatic, which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
2. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
3. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
4. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
5. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
6. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
7. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
8. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
9. Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement
10. Omnitura Therapeutics Announces Private Placement Financing
11. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016  Dovetail Genomics™ LLC today ... beta program for a planned metagenomic genome assembly service. ... company,s metagenomic genome assembly method in a talk on ... Biology & Technology conference in Orlando, Fla. ... highly complex datasets is difficult. Using its proprietary ...
(Date:2/11/2016)... ... , ... Global Stem Cells Group, has announced ... new facility will provide advanced protocols and state-of-the-art techniques in cellular medicine, focusing ... The new GSCG clinic is headed by four prominent Ecuadorian physicians, including Pablo ...
(Date:2/10/2016)... , Feb.10, 2016 ASAE is introducing a ... Management Companies (AMC) the option of joining or renewing ... fee determined by staff size, every employee in any ... ASAE and reap all available member benefits.   ... new organizational membership options will allow organizations of any ...
(Date:2/10/2016)... ... 2016 , ... Benchmark Research, a fully-integrated network of ... principal investigators (PI) to the roles of Chief Medical Officer, Clinical Research and ... Chu, a Benchmark Research PI in the Austin office, will assume the role ...
Breaking Biology Technology:
(Date:1/21/2016)... January 21, 2016 ... new market research report "Emotion Detection and Recognition Market by ... Tools (Facial Expression, Voice Recognition and Others), Services, ... forecast to 2020", published by MarketsandMarkets, the global ... reach USD 22.65 Billion by 2020, at a ...
(Date:1/18/2016)... Jan. 18, 2016  Extenua Inc., a pioneering ... the use and access of ubiquitous on-premise and ... with American Cyber.  ... leading transformational C4ISR and Cyber initiatives in support ... latest proven technology solutions," said Steve Visconti ...
(Date:1/11/2016)... Calif. , Jan. 11, 2016 Synaptics ... human interface solutions, today announced that its ClearPad ® ... integration (TDDI) products won two separate categories in the ... Mobile Innovator and Best Technology Breakthrough. The Synaptics ® ... cost, a simplified supply chain, thinner devices, brighter displays ...
Breaking Biology News(10 mins):